Literature DB >> 17124079

Primary cutaneous T-cell lymphomas.

Steven T Rosen1, Christiane Querfeld.   

Abstract

Primary cutaneous T-cell lymphomas (CTCLs) encompass a clinically and biologically heterogeneous group of non-Hodgkin lymphomas (NHLs) defined by clonal proliferation of skin-homing malignant T lymphocytes and natural killer cells. They account for up to 75% to 80% of all cutaneous lymphomas. The current WHO-EORTC classification of cutaneous lymphomas with primary cutaneous manifestations lists 13 entities. The most common subtypes-mycosis fungoides, Sézary syndrome, primary cutaneous anaplastic large cell lymphoma, and lymphomatoid papulosis-which represent approximately 95% of CTCLs, will be discussed in the following review. Each entity has unique biological characteristics and clinical course. Topical and/or systemic therapies are employed based on the stage of the disease and the tempo of progression.

Entities:  

Mesh:

Year:  2006        PMID: 17124079     DOI: 10.1182/asheducation-2006.1.323

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  9 in total

1.  Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells.

Authors:  Gabriel Brisou; Delphine Manzoni; Stephane Dalle; Pascale Felman; Dominique Morel; Marouane Boubaya; Jean Pierre Magaud; Lucile Baseggio
Journal:  J Clin Lab Anal       Date:  2014-03-20       Impact factor: 2.352

2.  Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity.

Authors:  Melissa G Lechner; Stephen Lade; Daniel J Liebertz; H Miles Prince; Garry S Brody; Howard R Webster; Alan L Epstein
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case.

Authors:  Melanie Pauline G Chao-Lo; Daisy King-Ismael; Rolando A Lopez
Journal:  J Dermatol Case Rep       Date:  2008-10-11

Review 4.  The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indications.

Authors:  Ercole Mazzeo; Laura Rubino; Michela Buglione; Paolo Antognoni; Stefano Maria Magrini; Francesco Bertoni; Manuela Parmiggiani; Paola Barbieri; Filippo Bertoni
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-13

5.  Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).

Authors:  Ulrik Ralfkiaer; Peter H Hagedorn; Nannie Bangsgaard; Marianne B Løvendorf; Charlotte B Ahler; Lars Svensson; Katharina L Kopp; Marie T Vennegaard; Britt Lauenborg; John R Zibert; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Rolf Søkilde; Lise M Gjerdrum; Tord Labuda; Anne-Merete Mathiesen; Kirsten Grønbæk; Mariusz A Wasik; Malgorzata Sokolowska-Wojdylo; Catherine Queille-Roussel; Robert Gniadecki; Elisabeth Ralfkiaer; Carsten Geisler; Thomas Litman; Anders Woetmann; Christian Glue; Mads A Røpke; Lone Skov; Niels Odum
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

6.  Testicular manifestation of a transformed mycosis fungoides.

Authors:  Hendrik Borgmann; Stefan Vallo; Christian Ruf; Anke Schmidt; Walter Ferdinand Thon
Journal:  Rare Tumors       Date:  2014-02-17

7.  Lymphomatoid papulosis misdiagnosed as pityriasis lichenoides et varioliformis acuta: Two case reports and a literature review.

Authors:  Yan Zheng; Jinjing Jia; Qiong Tian; Xinyu Dong; Xin Wang; Zhaoxia Ying; Shengxiang Xiao; Wensheng Li
Journal:  Exp Ther Med       Date:  2014-10-07       Impact factor: 2.447

8.  Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients.

Authors:  Iman Mamdouh Talaat; Rania ElSaied Abdelmaksoud; Maha Guimei; Naglaa Fathi Agamia; Ahmed Nugud; Ahmed Taher El-Serafi
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

9.  Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  David Kaminetzky; Kenneth B Hymes
Journal:  Biologics       Date:  2008-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.